Peninsula biotech space feels global pharma blues

Compugen's Mary Haak-Frendscho.

The patent expirations and capital efficiency trends sweeping through the global drug industry are playing out in companies’ local real estate decisions. That direction may not bode well in the short term for landlords and developers of biotech space on the Peninsula, with large biopharmaceutical companies buying tiny biotechs and consolidating multiple, smaller locations. But a new generation of biotech companies stands ready to take bits and pieces of the newly available space.